Navigation Links
The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
Date:10/4/2007

Free, Interactive Telephone Education Program Features Myeloma Experts,

Melissa Alsina, M.D. and Kathy A. Daily, R.N.

WHITE PLAINS, N.Y., Oct. 4 /PRNewswire/ -- Myeloma patients can learn about managing side effects during a free telephone education workshop sponsored by The Leukemia & Lymphoma Society, and led by myeloma experts Melissa Alsina, M.D., and Kathy A. Daily, R.N. of the H. Lee Moffitt Cancer & Research Institute.

"Managing Myeloma Side Effects: What you Need to Know," is scheduled for Wednesday, October 10, 2007, 12 noon -- 1:30 p.m. ET. Dr. Alsina, associate professor of medicine, for the bone marrow transplant program, and Kathy A. Daily, transplant nurse specialist, from the H. Lee Moffitt Cancer & Research Institute in Tampa, FL., will discuss diagnosis and treatment options of patients with myeloma, including information on emerging therapies under study. They will also discuss symptom and side effect management, information on the role of clinical trials and drug therapies in the advancement of myeloma treatment, and quality of life issues. A question-and-answer period will follow.

"The more information Myeloma patients have, the better decisions they can make in regard to treatment and side effect management," explains Robin Kornhaber, M.S.W., the Society's senior vice president of patient services. "We encourage patients, caregivers and healthcare providers to participate in this informative program."

This educational program is supported by Celgene and Millennium Pharmaceuticals. Nurses and social workers who participate in the program have an opportunity to earn 1.5 Continuing Education contact hours.

Registration

To register, call toll free by phone (866) 992-9950, ext. 304 or toll free by fax (888) 991-9951; email llsmyel@rmei.com (enter "Myeloma" in the subject field) or visit http://www.lls.org/myelomaeducation. Registrants will receive an information packet and toll free dial-in number within 7-10 days of signing up.

About Myeloma

Myeloma is a cancer of the plasma cells, a type of white blood cell found in many tissues of the body, but primarily in the bone marrow. In myeloma, a B lymphocyte, the cell that forms plasma cells, becomes malignant. It grows continuously and forms masses of plasma cells, especially in the marrow, destroying normal blood cell production.

Malignant plasma cells produce an abnormal protein called monoclonal immunoglobulin. Immunoglobulins (or antibodies) are an important part of the body's natural defense against infection because they recognize microbes that invade the body and permit then to be removed and destroyed. The onset of myeloma interferes with normal production of antibodies and makes myeloma patients susceptible to infections.

Often the first symptom of myeloma is bone pain caused by the effects of malignant plasma (myeloma) cells in the marrow. Patients may have anemia, tire more easily and feel weak. Fractures may occur as a result of the weakened bones. Recurrent infections may be an early sign of disease.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center staffed by Masters-level professionals who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. GLEEVEC - An Oral treatment for leukemia
2. GLEEVEC - An Oral treatment for leukemia
3. Looking Towards More Effective Leukemia Treatment
4. Cyclosporin A Treats Leukemia Complications
5. Exposure to EMF may cause leukemia
6. A new vaccine for leukemia
7. Leukemia pill shows promise against stomach cancer
8. Aspirin Lowers Leukemia Risk
9. Hope for Chemo-Resistant Leukemia Patients
10. Genes Found To Help Leukemia Treatment
11. Diet Found To Offer Protection Against Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... LLC to help enterprises move workloads to the cloud. Cirracore provides a ... their cloud without traversing the Internet. Transformation Solutions (TSL Partners) provides a ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), one ... ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient foundations ... , “Since our Pay It Forward program began, we are proud to have ...
(Date:2/9/2016)... ... ... On January 12, 2016 Paul McElwee, a CroppMetcalfe HVAC technician, visited a home ... any heat. Shortly after entering the home, Paul was able to identify the problem ... carbon monoxide into the home, at 2,000 parts per million in the flue. Anything ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. ... department stores, announced it has raised $176,000 to benefit the Breast Cancer Research ... Center at the University of Iowa, The Lynn Sage Cancer Research Foundation, and ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... "Company") (NASDAQ: UNIS ; ASX: UNS), a developer and ... for the second quarter of fiscal 2016 (three months ended December ... Financial Results for the Second Quarter of Fiscal 2016 ... the second quarter of fiscal 2016 was $4.5 million, compared to ... customers for the second quarter of fiscal 2016 were $17.8 million, ...
(Date:2/9/2016)... 2016  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced further details of three ... functional aspects of Lewy body dementia, a disease ... Two out of the three studies were recently ... later this quarter. In addition, the Company reported ...
(Date:2/9/2016)... Hearing protection devices refer to the barriers that reduce ... ear. Hearing protection devices include earplugs, uniform attenuation earplug, ... users exposed to noise levels of over 80 dB ... inserted in the ear canal to protect the ear. ... sound perception with the help of acoustic filters. Earmuffs ...
Breaking Medicine Technology: